Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy...

por Landry, Ishani, Nakai, Kenya, Ferry, Jim, Aluri, Jagadeesh, Hall, Nancy, Lalovic, Bojan, Moline, Margaret L.
Publicado 2020

Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer

por Farrell, Colm, Schweizer, Charles, Wustner, Jason, Weil, Susan, Namiki, Masayuki, Nakano, Tomohisa, Nakai, Kenya, Phillips, Martin D.
Publicado 2012

A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors

por Doi, Toshihiko, Aramaki, Takeshi, Yasui, Hirofumi, Muro, Kei, Ikeda, Masafumi, Okusaka, Takuji, Inaba, Yoshitaka, Nakai, Kenya, Ikezawa, Hiroki, Nakajima, Ryo
Publicado 2019

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant

por Landry, Ishani, Aluri, Jagadeesh, Nakai, Kenya, Hall, Nancy, Miyajima, Yukiko, Ueno, Takashi, Dayal, Satish, Filippov, Gleb, Lalovic, Bojan, Moline, Margaret, Reyderman, Larisa
Publicado 2021

Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma

por Kawai, Hidetsugu, Ando, Kiyoshi, Maruyama, Dai, Yamamoto, Kazuhito, Kiyohara, Eiji, Terui, Yasuhito, Fukuhara, Noriko, Miyagaki, Tomomitsu, Tokura, Yoshiki, Sakata‐Yanagimoto, Mamiko, Igarashi, Tadahiko, Kuroda, Junya, Fujita, Jiro, Uchida, Toshiki, Ishikawa, Takayuki, Yonekura, Kentaro, Kato, Koji, Nakanishi, Tadashi, Nakai, Kenya, Matsunaga, Risa, Tobinai, Kensei
Publicado 2021